Camizestrant + Ribociclib for Breast Cancer

(SERAFA-1 Trial)

This trial tests a new combination of two drugs, camizestrant and ribociclib, to evaluate their effectiveness in treating breast cancer that is positive for estrogen receptors (ER+) and negative for human epidermal growth factor receptor 2 (HER2-). The goal is to determine if this combination is effective and safe for individuals who have not tried other advanced treatments. This study suits those with newly advanced breast cancer that cannot be treated with surgery or radiation and who have not yet received systemic treatment. As a Phase 3 trial, it represents the final step before potential FDA approval, offering participants a chance to contribute to a treatment that may soon become widely available.

The trial requires a 2-week period without taking tamoxifen before starting the study treatment. Other current medications are not specifically mentioned, so it's best to discuss with the trial team.

Research has shown that the combination of camizestrant and ribociclib is generally well-tolerated by patients. In earlier studies, participants taking ribociclib experienced common side effects like tiredness, nausea, and low white blood cell counts. However, regular check-ups and supportive care mostly managed these effects.

When studied alone, camizestrant caused mild to moderate side effects, such as hot flashes and tiredness. Since this trial is in an advanced phase, earlier studies have already provided some reassurance about its safety. While some side effects are expected, the focus remains on managing them effectively as part of the treatment process.

Researchers are excited about camizestrant and ribociclib for breast cancer because these treatments work in a unique way compared to the standard options. Camizestrant is a next-generation oral SERD (Selective Estrogen Receptor Degrader), designed to degrade the estrogen receptor more effectively, potentially offering better results than older therapies like tamoxifen or aromatase inhibitors. Ribociclib, on the other hand, is a CDK4/6 inhibitor that helps stop cancer cell division, and when combined with camizestrant, it can target cancer cells from multiple angles. This combination has the potential to be more effective against certain types of breast cancer, especially those resistant to current hormone therapies.

Research has shown that the combination of camizestrant and ribociclib, which participants in this trial will receive, may be promising for treating a type of advanced breast cancer called ER+ HER2-. Studies have found that this combination can reduce the risk of the cancer worsening or causing death by 55-56% compared to other treatments. In another study, nearly half of the patients (49.5%) benefited from the treatment, and on average, their cancer did not worsen for 7.4 months. The treatment was generally well-tolerated, with most patients not experiencing severe side effects. Overall, these findings suggest that camizestrant and ribociclib could be effective options for patients with this type of breast cancer.¹²³⁴⁵